The effects of magnesium and vitamin E co-supplementation on parameters of glucose homeostasis and lipid profiles in patients with gestational diabetes.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

The aim of this study was to determine the effects of magnesium and vitamin E co-supplementation on metabolic status of women with gestational diabetes (GDM).

Participants' blood samples were taken to determine their metabolic profiles.

Who Took Part

The abstract describes 60 subjects taking part.

PubMed indexes the participants as adults, women only.

This randomized, double-blinded, placebo-controlled trial was conducted among 60 subjects diagnosed with GDM, aged 18-40 years.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The subjects were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Neither the subjects nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

What Was Measured

PubMed files the paper under topics including Cholesterol, HDL, Diabetes, Gestational, Dietary Supplements, Homeostasis, Lipids, Lipoproteins, LDL and Lipoproteins, VLDL.

Author keywords: Gestational diabetes, Insulin and Supplementation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 60 subjects.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2018 (Lipids in health and disease), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.